✦ LIBER ✦

Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice

✍ Scribed by Kosloski, Matthew P.; Pisal, Dipak S.; Mager, Donald E.; Balu-Iyer, Sathy V.

Book ID: 121379153
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 414 KB
Volume: 35
Category: Article
ISSN: 0142-2782
DOI: 10.1002/bdd.1880

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PEGylation of a Factor VIII–Phosphatidyl

PEGylation of a Factor VIII–Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice

✍ Aaron Peng; Matthew P. Kosloski; Genki Nakamura; Hong Ding; Sathy V. Balu-Iyer 📂 Article 📅 2011 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 233 KB

Phosphatidylinositol Containing Lipidic

Phosphatidylinositol Containing Lipidic Particles Reduces Immunogenicity and Catabolism of Factor VIII in Hemophilia A Mice

✍ Aaron Peng; Robert M. Straubinger; Sathy V. Balu-Iyer 📂 Article 📅 2010 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 246 KB

Safety and pharmacokinetics of a recombi

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A

✍ J. S. POWELL; D. J. NUGENT; J. A. HARRISON; A. SONI; A. LUK; H. STASS; E. GORINA 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB

Effect of route of administration of hum

Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice

✍ Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,

Studies on factor VIII activation potent

Studies on factor VIII activation potential in hemophilia A-plasma and its significance for the comprehension of hemophilia

✍ Ann-Marie Mingers 📂 Article 📅 1976 🏛 Springer 🌐 English ⚖ 629 KB

In a factor VIII exchange test experiment higher factor VIII activities are measurable than would be expected from the single activities of the used plasmas. The same goes for the use of plasmas from carriers of hemophilia A, but not for plasmas from patients with v.W.J.S. (von-Willebrand Jürgens sy

Influence of aggregation on immunogenici

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice

✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg